대한신장학회

Skip Navigation: Skip to contents

KOR
ENG
전체메뉴보기

간행물 검색

현재 페이지 경로

HOME
간행물
간행물 검색

논문분류	춘계학술대회 초록집
제목	The effects of pazopanib versus sunitinib on renal outcome in metastatic renal cell carcinoma
저자	Eun jeong LEE, *Jung eun LEE
출판정보	2017; 2017(1):
키워드	renal cell carcinoma, pazopanib, sunitinib, chronic kidney disease
초록	Objectives : Pazopanib and sunitinib are used as the first-line treatment of metastatic renal cell carcinoma (mRCC). With clinical outcome of mRCC has been improved by current targeted therapies, proper selection of therapy and management of toxicities are highlighted recently. Several studies have reported similar efficacy with a favorable safety profile of pazopanib. The aim of this study was to compare the renal outcome after pazopanib versus sunitinib treatment in patients with mRCC Methods : We reviewed medical records of 304 patients with metastatic renal cell carcinoma who received pazopanib (n=103) or sunitinib (n=201) therapy from 2007 to 2016. Chronic kidney disease (CKD) progression was defined as a drop in glomerular filtration rate (GFR) category accompanied by a 25% or greater drop in GFR from baseline, during treatment. We compared the proportion of CKD progression between two groups and evaluated related risk factors among patients who received drugs more than 1 month. We also evaluated estimated GFR as time sequence between two groups. Results : Overall, 47% of subjects had CKD stage 3 or 4 at baseline. Distributions of CKD stage were similar between two treatment groups. Treatment durations were 363 (129 ~ 504) days in pazopanib group and 360 (91 ~ 510) days in sunitinib group. Incidence of CKD progression was 19% in pazopanib group 17% in sunitinib group at 1 year after treatment (p = 0.083 by log rank test). Lower serum albumin levels and older age were independent risk factors of CKD progression. There was no statistical difference between two groups in deterioration of estimated GFR as time sequence at baseline, 3 month, 6 month, 12 month after treatment (p = 0.464, by mixed linear mixed model) Conclusions : The effects of pazopanib versus sunitinib treatment on CKD progression were similar in real-world practice. We suggest that there is no preference for selection of first line treatment for mRCC with regards to renal impairment.
원문(PDF)	PDF 원문보기

목록

위로가기